ABO blood group and effectiveness of tocilizumab in clinical response to COVID-19: A single center, retrospective study

Q4 Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical Sciences Asia Pub Date : 2023-01-01 DOI:10.29090/psa.2023.03.22.331

Izza Aulia Rizqika Nasution, R. Andrajati, N. F. Syafhan, R. Imaniar

引用次数: 0

Abstract

As an anticytokine therapy, tocilizumab has been recommended for the management therapy in patients with severe and serious COVID-19 cases. The association between the severity of COVID-19 and blood groups has been the subject of prior research. Therefore, it is important to analyze the relationship between blood types and the effectiveness of tocilizumab (TCZ) therapy in COVID-19 patients. This research involved 68 patients diagnosed with severe and critical COVID-19 receiving Tocilizumab (TCZ) therapy at Universitas Indonesia Hospital. Blood type O was associated with a significantly improvement in CRP levels ( P =0.014) and has better favorable outcomes compared to other blood type in terms of WHO Clinical Progression Scale (OR: 1.254, 95% CI: 0.457-3.443; P =0.797), length of stay (OR: 5,333, 95% CI: 0.495-3,734; P =0.614), and improvement in CRP levels (OR: 5,333, 95% CI: 1.385-20,541

查看原文本刊更多论文

ABO血型和托珠单抗在COVID-19临床反应中的有效性:一项单中心回顾性研究

作为一种抗细胞因子疗法，托珠单抗已被推荐用于重症和重度COVID-19患者的管理治疗。COVID-19严重程度与血型之间的关系一直是先前研究的主题。因此，分析COVID-19患者血型与托珠单抗(TCZ)治疗效果的关系具有重要意义。这项研究涉及68名在印度尼西亚大学医院接受Tocilizumab (TCZ)治疗的重症和危重型COVID-19患者。O型血与CRP水平的显著改善相关(P =0.014)，与其他血型相比，在WHO临床进展量表(OR: 1.254, 95% CI: 0.457-3.443;P =0.797)，住院时间(OR: 5,333, 95% CI: 0.495-3,734;P =0.614)， CRP水平的改善(OR: 5,333, 95% CI: 1.385-20,541)

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical Sciences Asia Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： The Pharmaceutical Sciences Asia (PSA) journal is a double-blinded peer-reviewed journal in English published quarterly, by the Faculty of Pharmacy, Mahidol University, Thailand. The PSA journal is formerly known as Mahidol University Journal of Pharmaceutical Sciences and committed to the timely publication of innovative articles and reviews. This journal is available in both printed and electronic formats. The PSA journal aims at establishing a publishing house that is open to all. It aims to disseminate knowledge; provide a learned reference in the field; and establish channels of communication between academic and research expert, policy makers and executives in industry and investment institutions. The journal publishes research articles, review articles, and scientific commentaries on all aspects of the pharmaceutical sciences and multidisciplinary field in health professions and medicine. More specifically, the journal publishes research on all areas of pharmaceutical sciences and related disciplines: Clinical Pharmacy Drug Synthesis and Discovery Targeted-Drug Delivery Pharmaceutics Biopharmaceutical Sciences Phytopharmaceutical Sciences Pharmacology and Toxicology Pharmaceutical Chemistry Nutraceuticals and Functional Foods Natural Products Social, Economic, and Administrative Pharmacy Clinical Drug Evaluation and Drug Policy Making Antimicrobials, Resistance and Infection Control Pharmacokinetics and Pharmacodynamics.